Core F: Biomarker Core

核心 F：生物标志物核心

• 批准号: 10264193
• 负责人: GENE E ALEXANDER
• 金额: $ 97.36万
• 依托单位: ARIZONA STATE UNIVERSITY-TEMPE CAMPUS
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-09-05 至 2026-06-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10264193
• 关键词: Address; Alzheimer disease prevention; Alzheimer' s Disease; Amyloid; Archives; Arizona; Behavioral; Biological; Biological Markers; Blood; Blood specimen; Brain; Brain imaging; Cerebrospinal Fluid; Clinical; Clinical Data; Cognitive; Collection; Communities; DNA; Data; Detection; Development; Diagnosis; Disease; Early Diagnosis; Elderly; Enrollment; Evaluation; Fostering; Funding; Genetic Risk; Goals; Grant; Image Analysis; Individual; Liquid substance; Longitudinal cohort; MRI Scans; Magnetic Resonance Imaging; Mission; Participant; Pathology; Peripheral Blood Mononuclear Cell; Plasma; Positron-Emission Tomography; Preparation; Prevention therapy; Prevention trial; Research; Research Personnel; Resource Sharing; Resources; Risk; Role; Sampling; Scanning; Specimen; Spottings; Standardization; Students; Technology; Training Support; Validation; Work; actigraphy; base; biomarker validation; blood-based biomarker; cohort; data analysis pipeline; design; digital; early detection biomarkers; end of life; follow-up; image processing; neuroimaging; neuropathology; pre-clinical; preclinical study; prevention evaluation; programs; research study; tau Proteins; training opportunity

PROJECT SUMMARY/ABSTRACT - BIOMARKER CORE The Biomarker Core (BC) will provide access across the Arizona ADRC to advance brain imaging, fluid, and wearable/digital biomarker expertise, resources, data, and specimens for application with our center and complementary affiliated cohorts to support NIA ADRC program goals. The Arizona ADRC has a major thematic focus on advancing efforts in the use of blood-based biomarkers (BBBs) in the diagnosis, preclinical study and prevention of AD. The BC will facilitate this thematic focus by supporting ADRC researchers in their efforts to: 1) further clarify the cognitive and biological changes associated with preclinical AD; 2) validate and clarify the role of new brain imaging, CSF, and blood-based biomarkers in the early detection and tracking of AD and to evaluate the potential of wearable/digital technologies as behavioral AD biomarkers; 3) inform the design, endpoints, and statistical power of prevention trials in individuals at different levels of AD risk to support our goal of finding effective AD prevention therapies; and 4) provide a valuable shared resource for Arizona ADRC researchers, the NIA ADRC program nationally, and researchers around the world studying AD and related disorders. To achieve these goals, the BC will support the standardized acquisition, processing, and analysis of amyloid PET, tau PET, and MRI; the standardized collection, preparation, storage, and analysis of blood, CSF, and DNA samples; and the acquisition, processing, and analysis of wearable/digital behavioral biomarkers in clinically well-characterized ADRC participants, many of whom have also agreed to brain donation. The BC will maintain a strong relationship with NCRAD for the processing and banking of blood and CSF samples and will fully support the NIA SCAN initiative for the sharing and archiving of ADRC BC neuroimaging scans with NACC. The BC will provide expertise and support to help ADRC researchers fully utilize the core resources and will work with each of the Arizona ADRC Cores, as well as investigators within and outside Arizona, to advance AD-related research. The BC will address the following specific aims: 1) to provide access to amyloid and tau PET, MRI scans, CSF and blood samples, and wearable/digital activity data across the Arizona ADRC; 2) to make available for research neuroimaging data, fluid specimens and biomarkers, and wearable/digital activity data from clinically well-characterized ADRC participants; 3) to support the development, evaluation, and implementation of blood-based biomarkers for early detection and tracking of AD risk and pathology; 4) to provide a resource of expertise and support for brain image processing and analysis for use in AD-related research studies; and 5) to foster collaborative research by working closely with each of the Arizona ADRC Cores, as well as users of these core resources inside and outside Arizona.

项目总结/摘要-生物标志物核心 生物标志物核心（BC）将提供跨亚利桑那州ADRC的访问，以推进脑成像，流体， 可穿戴/数字生物标志物专业知识、资源、数据和标本，供我们中心应用， 补充附属队列，以支持NIA ADRC计划的目标。亚利桑那州ADRC有一个主要的 主题重点是推进基于血液的生物标志物（BBB）在诊断、临床前 研究和预防AD。BC将通过支持ADRC研究人员在他们的工作中促进这一主题重点。 努力：1）进一步阐明与临床前AD相关的认知和生物学变化; 2）验证和 阐明新的脑成像，CSF和血液生物标志物在早期检测和跟踪中的作用。 AD并评估可穿戴/数字技术作为行为AD生物标志物的潜力; 3）告知 在不同AD风险水平的个体中进行预防试验的设计、终点和统计功效，以支持 我们的目标是找到有效的AD预防疗法; 4）为亚利桑那州提供宝贵的共享资源 ADRC研究人员，NIA ADRC计划，以及世界各地研究AD和 相关疾病。为了实现这些目标，BC将支持标准化的采集、处理和 淀粉样蛋白PET、tau PET和MRI的分析; 血液、CSF和DNA样本;以及可穿戴/数字行为的采集、处理和分析。 在临床特征良好的ADRC参与者中，许多人也同意脑 捐赠。BC将在血液处理和储存方面与NCRAD保持密切关系， CSF样本，并将全力支持NIA SCAN倡议，以共享和存档ADRC BC NACC的神经影像学扫描BC将提供专业知识和支持，以帮助ADRC研究人员充分 利用核心资源，并将与亚利桑那州ADRC核心的每一个，以及调查人员在 和亚利桑那州以外的地区，以推进广告相关的研究。小组委员会将致力达致以下具体目标： 提供淀粉样蛋白和tau PET、MRI扫描、CSF和血液样本以及可穿戴/数字活动数据的访问 整个亚利桑那州ADRC; 2）提供用于研究的神经成像数据，液体标本和 生物标志物，以及来自临床特征良好的ADRC参与者的可穿戴/数字活动数据; 3） 支持基于血液的生物标志物的开发、评估和实施，以实现早期检测， 跟踪AD风险和病理学; 4）为大脑图像处理提供专业知识和支持资源 及分析，以供与广告有关的研究之用;及5）透过紧密合作，促进合作研究 与每个亚利桑那州ADRC核心，以及亚利桑那州内外的这些核心资源的用户。